5/16
08:14 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
5/15
07:12 am
caba
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/15
07:00 am
caba
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
5/13
08:00 am
caba
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Low
Report
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
5/10
10:25 pm
caba
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology [Yahoo! Finance]
Low
Report
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology [Yahoo! Finance]
4/5
10:26 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
4/4
12:33 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.
3/22
02:32 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
3/22
01:46 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.
3/22
11:19 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
3/21
07:17 am
caba
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/21
07:00 am
caba
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/20
07:12 am
caba
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis [Yahoo! Finance]
Low
Report
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis [Yahoo! Finance]
3/20
07:00 am
caba
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Low
Report
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
2/27
10:29 am
caba
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 [Yahoo! Finance]
Low
Report
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 [Yahoo! Finance]
2/27
08:00 am
caba
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Low
Report
Cabaletta Bio to Participate in Upcoming Investor Conferences in March